Arbour Group to offer regulatory compliance software services to Impax Labs
Arbour Group, a provider of regulatory products and services for pharmaceutical, medical device and biotechnology companies worldwide, has concluded a project to offer regulatory compliance services for Impax Laboratories related to SAP enterprise software deployment.
Impax, a manufacturer of both brand and generic drug products, has implemented SAP to derive the benefits of tighter integration of global processes, accelerate the adoption of best practices and enhance quality and compliance.
Arbour Group utilized its proprietary SAP EzLifeSciences GMP and SOX Compliance Packages as the basis for financial testing and validating version 6.0.
The SAP Compliance Packages consist of templates and pre-written tests scripts that result in reduced time to develop SOX and GMP documentation, reduced time for testing and streamlined integration into implementation processes.
Related Insight
Suppliers Directory
PleaseTech – Collaborative Review and Authoring Solutions
PleaseTech Ltd is a software products company offering unique software solutions for the collaborative review and co-authoring of documents and other content.
Automation > IT & Software > Suppliers
Trilogy Writing and Consulting - Medical Writing Consultancy
Trilogy is a medical writing consultancy. We work proactively with our clients to plan, coordinate and write their clinical documentation to meet aggressive timelines, with a readability that reduces the time for review and approval.
Automation > IT & Software > Suppliers
Modgraph Consultants - Chemistry, Cheminformatics and Molecular Modeling Software Solutions
Modgraph Consultants Ltd. is an international software company specialising in the pharmaceutical industry, offering software solutions in chemistry, cheminformatics and molecular modeling.
Automation > IT & Software > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
IT & Software Intelligence
Accuri Revolutionizes Flow Cytometry
Published by Accuri Cytometers
Automation > IT & Software > White Papers
Efficient Drug Registration Process Based on Document Management
Published by Infotehna Group
Automation > IT & Software > White Papers
eCTDmanager™ Suite: Comprehensive Submission Management Solution
Published by EXTEDO
Automation > IT & Software > White Papers
Understanding Pasteurisation and Sterilisation Processes
Published by Tecnosoft
Automation > IT & Software > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.